Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of$55.8 million Bolstered balance sheet and expanded institutional investor ownership through $50 million underwritten public offering of common stock; cash and cash equivalents of$113.4 million as of the end of the quarter Exhibit 99.1 "We are treme ...